Bios 2024 Co-Invest, LP has made headlines with its recent SEC filing reporting significant transactions involving warrants for common stock of Actuate Therapeutics, Inc. This filing, dated October 30, 2026, highlights the ongoing investment activities of the firm and indicates a strategic move within the pharmaceutical preparations sector.

Actuate Therapeutics, Inc., which operates in the pharmaceutical industry, is the issuer of the common stock involved in these transactions. The filing reveals that Bios 2024 Co-Invest, LP exercised warrants to acquire a total of 1,037,852 shares of Actuate's common stock at an exercise price of $0.5325 per share. This substantial acquisition reflects the firm’s confidence in Actuate's future prospects and potential growth.

The filing details that the transactions occurred on October 28, 2026, and were classified under the SEC Act of 1934. The warrants were directly held by Bios 2024 Co-Invest, LP, and the exercise of these warrants has resulted in the firm owning a significant number of shares in Actuate Therapeutics.

In total, the transactions included:

  • 64,995 shares acquired by Bios 2024 Co-Invest, LP
  • 87,743 shares acquired by Bios Actuate Co-Invest I, LP
  • 682,885 shares acquired by Bios Actuate Co-Invest II, LP
  • 194,984 shares acquired by Bios Actuate Co-Invest III, LP
  • 368,304 shares acquired by Bios Clinical Opportunity Fund, LP
  • 36056 shares acquired by Bios Fund II NT, LP
  • 269,342 shares acquired by Bios Fund II QP, LP
  • 82,018 shares acquired by Bios Fund I, LP
  • 47,972 shares acquired by Bios Fund I QP, LP

The impact of these transactions could be significant, affecting not only the financial structure of Actuate Therapeutics but also investor sentiment in the pharmaceutical preparations sector. As a major player in this industry, Actuate’s performance will be closely watched by investors and competitors alike.

Looking ahead, it remains to be seen how these acquisitions will influence Actuate's strategic direction and market positioning. The filing does not specify any further actions or upcoming events related to these transactions, leaving stakeholders to speculate on the potential implications.